** Shares of drug developer Atea Pharmaceuticals AVIR.O rise 6.9% to $3.72 premarket
** Co says its drug combination met the main goal for treating Hepatitis C Virus (HCV) in a mid-stage study
** The combination of bemnifosbuvir and ruzasvir showed 98% success rate in eliminating HCV, co says
** Bemnifosbuvir and ruzasvir are both oral antiviral medications to treat HCV
** HCV is a leading cause of chronic liver diseases and liver transplants, affecting around 50 mln people worldwide
** As of last close, stock had risen 14.1% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。